

### OHCA Strategy Forum October 11 - 12, 2017

**AGENDA: DAY 1** 

Time	Session	Presenter
8:30 - 9:00	Registration, Networking and Table Introductions	Table Facilitator All
9:00 - 9:25	Call Meeting to Order	Chairman Ed McFall Sharon Hsieh
	Welcome and Overview Presentation	Beth VanHorn Colleen Flory
9:25 - 9:50	Session 1: Vision of Success for OHCA Goals	Colleen Flory
9:50 - 10:05	BREAK	
10:05 - 11:20	Session 2: Develop Goal Information	Colleen Flory Table Groups
11:20 - 11:45	Session 3: OHCA Budget, Externalities and Constraints	Becky Ikard
11:45 - 1:00	LUNCH	
1:00 - 2:05	Session 4: Review and Elaborate on Focus Areas	Colleen Flory Table Groups
2:05 - 2:30	Session 5: Review OHCA Core Functions and Projects	Colleen Flory Table Groups
2:30 - 2:45	BREAK	
2:45 - 3:45	Session 6: Determine Impact of Core Functions and Projects on Focus Areas	Colleen Flory Table Groups
3:45 - 4:00	Closing	Colleen Flory
4:00	RECESS	Chairman Ed McFall



### OHCA Strategy Forum October 11 - 12, 2017

**AGENDA: DAY 2** 

Time	Session	Presenter
8:30 - 9:00	Reconvene Strategy Forum/Welcome	Chairman Ed McFall Table Facilitator
9:00 - 9:15	Session 7: Review Outcomes from Previous Day	Beth VanHorn Colleen Flory
9:15 - 10:00	Session 8: Determine Gaps and New Ideas for Focus Areas	Colleen Flory Table Groups
10:00 - 10:15	BREAK	
10:15 - 10:55	Session 9: Open Discussion of Items/Issues	Colleen Flory All
10:55 - 11:00	Closing	Colleen Flory
11:00	ADJOURN	Chairman Ed McFall

### OKLAHOMA HEALTH CARE AUTHORITY REGULARLY SCHEDULED BOARD MEETING

October 12, 2017 at 12:30 P.M. Oklahoma Health Care Authority 4345 N. Lincoln Blvd. OKC, OK

### AGENDA

### Items to be presented by Ed McFall, Chairman

- 1. Call to Order / Determination of Quorum
- 2. Action Item Approval of the September 27, 2017 OHCA Board Meeting Minutes

### Item to be presented by Becky Pasternik-Ikard, Chief Executive Officer

- 3. Discussion Item Chief Executive Officer's Report
  - a) Employee Recognition Becky Pasternik-Ikard, Chief Executive Officer
    - July All-Star Bev Reed, Financial Manager II Carrie Evans
  - b) Special Recognition Becky Pasternik-Ikard
  - c) Financial Update Carrie Evans, Chief Financial Officer
  - d) Medicaid Director's Update Garth Splinter, Deputy Chief Executive Officer
    - 1. MAU Transformation
    - 2. Tobacco Cessation Della Gregg, HMP Manager; Kelly Parker, SoonerQuit Health Promotion Grant Supervisor
  - e) Legislative Update Cate Jeffries, Interim Legislative Liaison

### <u>Item to be presented by Beverly Couch, Senior Research Analyst for Waiver Development & Reporting</u>

4. Discussion Item – Statewide Transition Plan Overview

### Item to be presented by Maria Maule, Deputy General Counsel

5. Announcements of Conflicts of Interest Panel Recommendations for All Action Items Regarding This Board Meeting.

### Item to be presented by Burl Beasley, Assistant Director of Pharmacy Services

- 6. Action Item Consideration and Vote Regarding Recommendations Made by the Drug Utilization Review Board Under 63 Oklahoma Statutes 5030.3.
  - a) Consideration and vote to add <u>Afstyla® [Antihemophilic Factor (Recombinant), Single Chain] and Rebinyn® [Coagulation Factor IX (Recombinant), GlycoPEGylated]</u> to the utilization and scope prior authorization program under OAC 317:30-5-77.2(e).

- b) Consideration and vote to add <u>Endari™ (L-Glutamine)</u> to the utilization and scope prior authorization program under OAC 317:30-5-77.2(e).
- c) Consideration and vote to add <u>Namenda XR® (Memantine Extended-Release Capsules)</u> to the utilization and scope prior authorization program under OAC 317:30-5-77.2(e).
- d) Consideration and vote to add <u>Fabrazyme® (Agalsidase Beta)</u> to the utilization and scope prior authorization program under OAC 317:30-5-77.2(e).
- e) Consideration and vote to add <u>Kisqali® (Ribociclib)</u>, <u>Kisqali® Femara® Co-Pack</u> (<u>Ribociclib/Letrozole</u>), and <u>Nerlynx™ (Neratinib)</u> to the utilization and scope prior authorization program under OAC 317:30-5-77.2(e).

### Item to be presented by Ed McFall, Chairman

- 7. New Business
- 8. ADJOURNMENT

NEXT BOARD MEETING
November 9, 2017
Oklahoma Health Care Authority
Oklahoma City, OK

### MINUTES OF A SCHEDULED BOARD MEETING OF THE HEALTH CARE AUTHORITY BOARD

September 27, 2017 Oklahoma Health Care Authority Boardroom Oklahoma City, Oklahoma

Manner and Time of Notice of Meeting: A statutorily required public meeting notice was placed on the front door of the Oklahoma Health Care Authority on September 26, 2017 at 1:00 p.m. Advance public meeting notice was provided to the Oklahoma Secretary of State. In addition to the posting of the statutory public notice, the agency placed its agenda on its website on September 22, 2017 at 12:30 p.m.

Pursuant to a roll call of the members, a quorum was declared to be present, and Chairman McFall called the meeting to order at 1:06 p.m.

BOARD MEMBERS PRESENT: Chairman McFall, Member Case, Member Nuttle, Member Robison

BOARD MEMBERS ABSENT: Vice-Chairman Armstrong, Member Bryant, Member McVay

OTHERS PRESENT: OTHERS PRESENT:

Mike Fogarty Mark DeClerk, Lilly Shannon Wilkinson, OHCA Marlene Asmussen

Rhonda C. Harjo, Chickasaw Nation Laura Dempsey, Morton Comprehensive Health Services

Harvey Reynolds, OHCA
Melinda Thomason, OHCA
Bill Garrison, OHCA

LeKenya Antwine, OHCA
David Ward, OHCA
Gloria LaFitte, OHCA

Lewis Robinson, OHCA Tammy Vaughn, Southeastern OK Family Services

Sherris Harris-Ososanya, OHCA Melissa McCully, OHCA

Rick Snyder, OHA Meg Wingerter, The Oklahoman

Thomas Nunn, DO, OHCA

Kelli Brodersen, OHCA

Jimmy Witcosky, OHCA

Mia Smith, OHCA

Dwyna Vick, OHCA

Brent Wilborn, OKPCA

## DISCUSSION AND POSSIBLE VOTE ON APPROVAL OF BOARD MINUTES OF THE REGULARY SCHEDULED BOARD MEETING HELD August 24, 2017.

The Board routinely reviews and approves a synopsis of all its meetings. The full-length recordings of the meetings of the Board are retained at the Board Offices and may be reviewed upon written request.

MOTION: Member Case moved for approval of the August 24, 2017 board meeting

minutes as published. The motion was seconded by Member Robison.

FOR THE MOTION: Chairman McFall, Member Nuttle

BOARD MEMBERS ABSENT: Vice-Chairman Armstrong, Member Bryant, Member McVay

### ITEM 3A / RECOGNITION OF 2017 GREAT 100 NURSES HONOREES

The following OHCA 2017 Great 100 Nurses were recognized

- Carolynn Reconnu-Shoffner, RN, BSN, CCM, Assistant Director of Population Care Management(PCM)
- Maria Gutierrez, RN, BSN, PCM Supervisor
- Becky Pasternik-Ikard, JD, MS, RN, Chief Executive Officer

#### ITEM 3B / ALL-STAR INTRODUCTION

The following OHCA All-Star was recognized

August All-Star – Demetria Bennett, Policy Development Coordinator (Tywanda Cox)

#### **ITEM 3C / FINANCIAL UPDATE**

Carrie Evans, Chief Financial Officer

Ms. Evans gave a brief update on OHCA's current finances. July financials were not presented as there has been light administrative spending. Ms. Evans will present August financials at the October Board meeting. OHCA is under budget in Medicaid program spending for July, August and September looks to be under budget as well. Ms. Evans presented a list of items we could implement should the \$70 million not be filled completely or at all in the future. For more detailed information, see Item 3c in the board packet.

### ITEM 3D / MEDICAID DIRECTOR'S UPDATE

Garth Splinter, Deputy Chief Executive Officer

Dr. Splinter provided an update for July 2017 data that included a report on the number of SoonerCare enrollees in different areas of the Medicaid program including total in-state providers. Dr. Splinter also presented charts showing monthly enrollment and monthly change in enrollment for Choice, Traditional and Insure Oklahoma For more detailed information, see Item 3d in the board packet.

#### ITEM 3E / LEGISLATIVE/BUDGET UPDATE

Cate Jeffries, Interim Legislative Liaison

Ms. Jeffries gave a brief update regarding the special session, which started September 25, 2017. About 196 measures have been filed. OHCA is tracking 35 of those bills and keeping an eye on 66 others that appear to be shell bills related to budget and government efficiency. HB 1099, the cigarette tax, passed through the House and Senate JCABs. The House recessed because an agreement could not be made. Three bills, identical to the Hope Act, have been introduced, one of which has been assigned a committee.

### ITEM 4 / ANNOUNCEMENTS OF CONFLICTS OF INTEREST PANEL RECOMMENDATIONS FOR ALL ACTION ITEMS

Nicole Nantois, Chief of Legal Services

There were no recommendations regarding conflicts.

### ITEM 5 / CONSIDERATION AND VOTE UPON THE RECOMMENDATIONS OF THE STATE PLAN AMENDMENT RATE COMMITTEE

Carrie Evans, Chief Financial Officer

a) Consideration and Vote for a rate change to increase the rate paid for private duty nursing (Procedure Code T1000) from \$6.30 per 15 min unit (\$25.20 / hour) to \$7.55 per 15 min unit (\$30.20 / hour). The estimated budget impact for state fiscal year 2018 is estimated to be \$0. This assumes increased costs from longer inpatient stays if there is no change.

MOTION: Member Case moved for approval of Item 5 as published. The motion

was seconded by Member Nuttle.

<u>FOR THE MOTION:</u> Chairman McFall, Member Robison

BOARD MEMBERS ABSENT: Vice-Chairman Armstrong, Member Bryant, Member McVay

# ITEM 6 / CONSIDERATION AND VOTE OF AGENCY RECOMMENDED RULEMAKING PURSUANT TO ARTICLE I OF THE ADMINISTRATIVE PROCEDURES ACT. THE AGENCY REQUESTS THE ADOPTION OF THE FOLLOWING EMERGENCY RULES

Tywanda Cox, Chief of Federal and State Policy

Action Item – a) Consideration and Vote upon a Declaration of a Compelling Public Interest for the promulgation of *all Emergency Rules* in item eight in accordance with 75 Okla. Stat. § 253.

Action Item – b) Consideration and Vote of Agency Recommended Rulemaking Pursuant to Article I of the Administrative Procedures Act. The Agency Requests the Adoption of the Following Emergency Rules:

### The following emergency rules HAVE NOT previously been approved by the Board.

a) AMENDING agency rules at OAC 317:45-11-20 to strengthen program integrity in the Insure Oklahoma Individual Plan. Revisions make it incumbent upon the self-employed applicant to verify self-employment by completing and submitting certain documentation. These revisions will help ensure that self-employed applicants are engaged in routine, for-profit activity, in accordance with Internal Revenue Service guidelines.

**Budget Impact: Budget neutral** 

#### (Reference APA WF # 17-02)

b) AMENDING agency rules at OAC 317:30-3-4.1 and 317:30-3-30 will clarify the authentication of electronic medical records. Current policy that became effective September 1, 2017 requires that the record be authenticated within three (3) days of the provision of the underlying service. New revisions will revert the three (3) day signature language to the policy that was in place on June 25, 2011. The proposed revisions will clarify that the authentication of medical records is expected on the day the record is completed. Additionally, revisions will describe that the signature of the rendering provider and date entry is expected within three (3) business days from the day the record is completed if the record is being transcribed.

**Budget Impact: Budget neutral** 

### (Reference APA WF # 17-13)

c) AMENDING agency rules at OAC 317:30-5-696 will clarify dental coverage for adults by amending the rule that limits dental services for adults to "emergency" extractions. The policy was initially intended for emergency extractions and was later revised to medically necessary extractions. The intent of the change was to ensure the emergency extractions were medically necessary; therefore, the policy will revert to the original language to include the term emergency along with reference to where emergency dental care is defined in policy. Additionally, the proposed revisions add new language on the medically necessary images and oral examination that can accompany an emergency extraction.

Budget Impact: Revisions will result in approximately \$479,017 of state share savings for eight months of SFY 2018.

(Reference APA WF # 17-14)

MOTION: Member Robison moved for approval of emergency rulemaking for Item

6a as published. The motion was seconded by Member Case.

FOR THE MOTION: Chairman McFall, Member Nuttle

BOARD MEMBERS ABSENT: Vice Chairman Armstrong, Member Bryant, Member McVay

MOTION: Member Nuttle moved for approval of emergency rulemaking for Item

6b.a-c as published. The motion was seconded by Member Case.

FOR THE MOTION: Chairman McFall, Member Robison

BOARD MEMBERS ABSENT: Vice Chairman Armstrong, Member Bryant, Member McVay

### ITEM 7A-E / CONSIDERATION AND VOTE REGARDING RECOMMENDATIONS MADE BY THE DRUG UTILIZATION BOARD UNDER 63 OKLAHOMA STATUTES 5030.3

Nancy Nesser, Pharmacy Director

- Consideration and vote to add Radicava™ (Edaravone) to the utilization and scope prior authorization program a) under OAC 317:30-5-77.2(e).
- Consideration and vote to add Eucrisa™ (Crisaborole 2% Ointment), Dupixent® (Dupilumab Injection), & b) Prudoxin™ and Zonalon® (Doxepin 5% Cream) to the utilization and scope prior authorization program under OAC 317:30-5-77.2(e).
- Consideration and vote to add Vimizim® (Elosulfase Alfa) to the utilization and scope prior authorization c) program under OAC 317:30-5-77.2(e).
- Consideration and vote to add Rayaldee® (Calcifediol), Parsabiv™ (Etelcalcetide), Zemplar® (Paricalcitol d) Capsules), and Hectorol® (Doxercalciferol Capsules) to the utilization and scope prior authorization program under OAC 317:30-5-77.2(e).
- Consideration and vote to add Brineura™ (Cerliponase Alfa) to the utilization and scope prior authorization e) program under OAC 317:30-5-77.2(e).

MOTION: Member Case moved for approval of Item 7a-e as published. The

motion was seconded by Member Robison.

Chairman McFall, Member Nuttle **FOR THE MOTION:** 

**BOARD MEMBERS ABSENT:** Vice Chairman Armstrong, Member Bryant, Member McVay

### ITEM 8 / PROPOSED EXECUTIVE SESSION AS RECOMMENDED BY THE CHIEF OF LEGAL SERVICES AND AUTHORIZED BY THE OPEN MEETINGS ACT, 25 OKLAHOMA STATUTES §307(B) (4)

Nicole Nantois, Chief of Legal Services

There was no executive session

### **ITEM 9 / NEW BUSINESS**

There was no new business.

#### **ITEM 10 / ADJOURNMENT**

Member Robison moved for approval for adjournment. The MOTION:

motion was seconded by Member Case.

Chairman McFall, Member Bryant, Member McVay, Member Robison FOR THE MOTION:

**BOARD MEMBERS ABSENT:** Vice Chairman Armstrong

Meeting adjourned at 2:03 p.m., 09/27/2017

**NEXT BOARD MEETING** ity

	October 12, 2017 Oklahoma Health Care Authori Oklahoma City, OK
Martina Ordonez Board Secretary	
Minutes Approved:	
Initials:	



### FINANCIAL REPORT

For the Two Months Ended August 31, 2017 Submitted to the CEO & Board

- Revenues for OHCA through August, accounting for receivables, were \$790,336,368 or .5% under budget.
- Expenditures for OHCA, accounting for encumbrances, were \$729,164,693 or 1.7% under budget.
- The state dollar budget variance through August is a **positive** \$8,188,394.
- The budget variance is primarily attributable to the following (in millions):

Expenditures:	
Medicaid Program Variance	4.1
Administration	.5
Revenues:	
Drug Rebate	1.9
Taxes and Fees	1.2
Overpayments/Settlements	.5
Total FY 17 Variance	\$ 8.2

#### **ATTACHMENTS**

Summary of Revenue and Expenditures: OHCA	1
Medicaid Program Expenditures by Source of Funds	2
Other State Agencies Medicaid Payments	3
Fund 205: Supplemental Hospital Offset Payment Program Fund	4
Fund 230: Quality of Care Fund Summary	5
Fund 245: Health Employee and Economy Act Revolving Fund	6
Fund 250: Belle Maxine Hilliard Breast and Cervical Cancer	
Treatment Revolving Fund	7

# OKLAHOMA HEALTH CARE AUTHORITY Summary of Revenues & Expenditures: OHCA SFY 2018, For the Two Month Period Ending August 31, 2017

		FY18			% Over/
		Actual YTD		Variance	(Under)
13	\$	220,037,313	\$	-	0.0
93		415,563,412		(11,425,281)	(2.7)
43		9,585,297		1,363,754	16.6
43		13,019,276		(104,767)	(0.8)
60		29,000,260		-	0.0
42		45,242		-	0.0
91		32,538,958		4,690,567	16.8
14		6,463,780		1,296,666	25.1
22		60,401,222		-,200,000	0.0
41		3,681,608		(21,033)	(0.6)
61	\$	790,336,368	\$	(4,200,094)	(0.5
		FY18			% (Over)/
		Actual YTD		Variance	Under
	\$	8,495,879	\$	790,126	8.5
21		17,513,363		655,358	3.0
82		7,452,931		230,352	3.0
87		149,152,327		(1,535,240)	(1.0
88		3,615,745		(147,258)	(4.2
57		65,864,802		5,924,055	8.
94		22,415,851		(638,356)	(2.9
40		9,403,240		92,400	1.
70		2,861,725		45,345	1.
31		4,794,294		701,437	12.
97		8,710,301		(160,904)	(1.9
41		31,384,174		2,594,466	7.
35		96,432,020		4,085,915	4.
00		751		1,249	0.
<b>5</b> 0		04 004 540		202.042	0
53 66		94,631,512		263,642	0.
66 27		10,251,261		433,305	4.
37 86		28,872,031		(75,193)	(0.3
86		11,076,555		(8,969)	(0.1
86		51,606		(10,620)	0.
74		3,301,674		- (100.07.1)	0.
41		18,002,495		(139,054)	8.0)
47		132,313,947		-	0.
60		2,566,210		(802,950)	(45.5
72		703,155,451		10,853,621	1.
82		-		89,382	0.
80	\$	729,164,693	\$	12,388,487	1.
	80	80 \$	80 \$ 729,164,693	80 \$ 729,164,693 \$	80 \$ 729,164,693 \$ 12,388,487

### **OKLAHOMA HEALTH CARE AUTHORITY**

# Total Medicaid Program Expenditures by Source of State Funds SFY 2018, For the Two Month Period Ending August 31, 2017

		Health Care	Quality of		SHOPP	BCC	Other State
Category of Service	Total	Authority	Care Fund	HEEIA	Fund	Revolving Fund	Agencies
SoonerCare Choice	\$ 7,474,267	\$ 7,450,757	\$ - \$	21,336	\$ -	\$ 2,174	\$ -
Inpatient Acute Care	262,706,712	97,275,244	81,114	564,047	98,873,320	124,146	65,788,840
Outpatient Acute Care	77,877,567	51,090,085	6,934	668,699	25,537,046	574,802	-
Behavioral Health - Inpatient	11,202,389	2,156,505	-	65,989	7,574,695	-	1,405,200
Behavioral Health - Psychiatrist	1,788,126	1,459,240	-		328,886	-	-
Behavioral Health - Outpatient	2,633,565	-	-	-	-	-	2,633,565
Behaviorial Health-Health Home	8,747,246	-	-	-	_	-	8,747,246
Behavioral Health Facility- Rehab	31,885,176	-	-	-	_	13,077	31,885,176
Behavioral Health - Case Management	2,759,511	-	-	-	_	, -	2,759,511
Behavioral Health - PRTF	10,228,710	-	-	-	_	-	10,228,710
Behavioral Health - CCBHC	11,302,014	-					11,302,014
Residential Behavioral Management	3,097,325	-	-	-	-	-	3,097,325
Targeted Case Management	10,071,149	-	-	-	_	_	10,071,149
Therapeutic Foster Care	751	751	-	-	-	-	-
Physicians	77,118,396	64,999,263	9,683	806,838	-	855,855	10,446,756
Dentists	22,424,827	22,413,753	-	8,976	-	2,098	-
Mid Level Practitioners	439,995	436,337	-	3,462	-	197	-
Other Practitioners	9,051,593	8,872,801	74,394	84,886	-	19,511	-
Home Health Care	2,862,222	2,861,620	-	496	-	105	-
Lab & Radiology	4,929,166	4,759,421	-	134,872	-	34,873	-
Medical Supplies	8,780,953	8,253,022	451,922	70,652	-	5,358	-
Clinic Services	32,219,508	30,185,723	-	196,688	-	30,102	1,806,996
Ambulatory Surgery Centers	1,198,392	1,167,299	-	30,042	-	1,051	
Personal Care Services	1,989,757	-	-	-	-	-	1,989,757
Nursing Facilities	94,631,512	57,647,352	36,976,544	-	-	7,616	-
Transportation	11,075,510	10,650,520	388,351	18,090	-	18,550	-
GME/IME/DME	44,484,650	-	-	-	-	-	44,484,650
ICF/IID Private	10,251,261	8,346,937	1,904,325	-	-	-	-
ICF/IID Public	1,621,348	-	-	-	-	-	1,621,348
CMS Payments	46,874,526	46,739,757	134,768	-	-	-	-
Prescription Drugs	98,549,318	95,952,499	-	2,117,298	-	479,521	-
Miscellaneous Medical Payments	19,135	18,269	-	-	-	866	-
Home and Community Based Waiver	34,355,749	-	-	-	-	-	34,355,749
Homeward Bound Waiver	13,714,129	-	-	-	-	-	13,714,129
Money Follows the Person	51,606	51,606	-	-	-	-	-
In-Home Support Waiver	4,296,957	-	-	-	-	-	4,296,957
ADvantage Waiver	30,369,220	-	-	-	-	-	30,369,220
Family Planning/Family Planning Waiver	957,613	-	-	-	-	-	957,613
Premium Assistance*	9,953,673	-	-	9,953,673	-	-	-
Telligen	2,566,210	2,566,210	-	-	-	-	-
Electronic Health Records Incentive Payments	3,301,674	3,301,674					
Total Medicaid Expenditures	\$ 1,009,863,404	\$ 528,656,645	\$ 40,028,035 \$	14,746,045	\$ 132,313,947	\$ 2,169,900	\$ 291,961,909

<sup>\*</sup> Includes \$9,879,671.49 paid out of Fund 245

### **OKLAHOMA HEALTH CARE AUTHORITY**

# Summary of Revenues & Expenditures: Other State Agencies

SFY 2018, For the Two Month Period Ending August 31, 2017

REVENUE		FY18 Actual YTD
Revenues from Other State Agencies	\$	112,907,4
Federal Funds		179,436,5
TOTAL REVENUES	\$	292,343,9
XPENDITURES		Actual YTD
Department of Human Services		
Home and Community Based Waiver	\$	34,355,7
Money Follows the Person		
Homeward Bound Waiver		13,714,1
In-Home Support Waivers		4,296,9
ADvantage Waiver		30,369,2
Intermediate Care Facilities for Individuals with Intellectual Disabilities Public		1,621,3
Personal Care		1,989,7
Residential Behavioral Management		1,540,5
Targeted Case Management  Total Department of Human Services		8,694,6 <b>96,582,</b> 3
Total Department of Human Services		90,562,5
State Employees Physician Payment		
Physician Payments		10,446,7
Total State Employees Physician Payment		10,446,7
Education Payments		
Graduate Medical Education		25,162,7
Graduate Medical Education - Physicians Manpower Training Commission		2,315,3
Indirect Medical Education		17,006,6
Direct Medical Education		
Total Education Payments		44,484,6
Office of Juvenile Affairs		
Targeted Case Management		386,5
Residential Behavioral Management		1,556,7
Total Office of Juvenile Affairs		1,943,3
Department of Mantal Haalth		
Department of Mental Health Case Management		2,759,5
Inpatient Psychiatric Free-standing		1,405,2
Outpatient		2,633,5
Health Homes		2,033,3 8,747,2
Psychiatric Residential Treatment Facility		10,228,7
Certified Community Behavioral Health Clinics		11,302,0
Rehabilitation Centers		31,885,1
Total Department of Mental Health		68,961,4
State Department of Health Children's First		220.0
Sooner Start		229,9 1,377,7
Early Intervention		743,4
Early and Periodic Screening, Diagnosis, and Treatment Clinic		316,3
Family Planning		42,2
Family Planning  Family Planning Waiver		909,8
Maternity Clinic		1,2
Total Department of Health		3,620,9
County Hoalth Donartmants		
County Health Departments  EPSDT Clinic		111,6
LI JUT CIIIIC		5,4
Family Planning Waiyer		117,0
Family Planning Waiver Total County Health Departments		,
Family Planning Waiver Total County Health Departments		
Total County Health Departments  State Department of Education		
Total County Health Departments  State Department of Education Public Schools		16,4
Total County Health Departments  State Department of Education Public Schools Medicare DRG Limit		16,4 65,000,0
Total County Health Departments  State Department of Education Public Schools Medicare DRG Limit Native American Tribal Agreements		-
Total County Health Departments  State Department of Education Public Schools Medicare DRG Limit Native American Tribal Agreements Department of Corrections		65,000,0
Total County Health Departments  State Department of Education Public Schools Medicare DRG Limit Native American Tribal Agreements		65,000,0
Total County Health Departments  State Department of Education Public Schools Medicare DRG Limit Native American Tribal Agreements Department of Corrections	\$	=
Total County Health Departments  State Department of Education Public Schools Medicare DRG Limit Native American Tribal Agreements Department of Corrections JD McCarty  Total OSA Medicaid Programs	•	788,8 291,961,9
Total County Health Departments  State Department of Education Public Schools Medicare DRG Limit Native American Tribal Agreements Department of Corrections JD McCarty	\$ \$	65,000,0 788,8

Fund 205: Supplemental Hospital Offset Payment Program Fund SFY 2018, For the Two Month Period Ending August 31, 2017

REVENUES	FY 18 Revenue
SHOPP Assessment Fee	\$ 60,362,767
Federal Draws	79,308,980
Interest	29,812
Penalties	8,643
State Appropriations	(7,550,000)
TOTAL REVENUES	\$ 132,160,201

EXPENDITURES	Quarter	E	FY 18 Expenditures
Program Costs:  Hospital - Inpatient Care Hospital -Outpatient Care Psychiatric Facilities-Inpatient Rehabilitation Facilities-Inpatient Total OHCA Program Costs	7/1/17 - 9/30/17 98,873,320 25,537,046 7,574,695 328,886 132,313,947	\$	98,873,320 25,537,046 7,574,695 328,886 132,313,947
Total Expenditures		\$	132,313,947
CASH BALANCE		\$	(153,745)

Fund 230: Nursing Facility Quality of Care Fund SFY 2018, For the Two Month Period Ending August 31, 2017

REVENUES	Total State Revenue Share
Quality of Care Assessment	\$ 13,012,582 \$ 13,012,582
Interest Earned	6,695 6,695
TOTAL REVENUES	\$ 13,019,276 \$ 13,019,276

EXPENDITURES	,	FY 18 Total \$ YTD	5	FY 18 State \$ YTD	S	Total
Program Costs						
Nursing Facility Rate Adjustment	\$	36,367,031	\$	14,568,632		
Eyeglasses and Dentures		46,513		18,633		
Personal Allowance Increase		563,000		225,538		
Coverage for Durable Medical Equipment and Supplies		451,922		181,040		
Coverage of Qualified Medicare Beneficiary		172,126		68,954		
Part D Phase-In		134,768		53,988		
ICF/IID Rate Adjustment		905,800		362,863		
Acute Services ICF/IID		998,525		400,009		
Non-emergency Transportation - Soonerride		388,351		155,573		
Total Program Costs	\$	40,028,035	\$	16,035,231	\$	16,035,231
Administration						
OHCA Administration Costs	\$	88,682	\$	44,341		
DHS-Ombudsmen	•	, -	·	-		
OSDH-Nursing Facility Inspectors		-		-		
Mike Fine, CPA		-		-		
Total Administration Costs	\$	88,682	\$	44,341	\$	44,341
Total Quality of Care Fee Costs	\$	40,116,717	\$	16,079,572		
TOTAL STATE SHARE OF COSTS					\$	16,079,572

Note: Expenditure amounts are for informational purposes only. Actual payments are made from Fund 340. Revenues deposited into the fund are transferred to Fund 340 to support the costs, not to exceed the calculated state share amount.

Fund 245: Health Employee and Economy Improvement Act Revolving Fund SFY 2018, For the Two Month Period Ending August 31, 2017

REVENUES	FY 17 Carryover	FY 18 Revenue	Total Revenue
Prior Year Balance	\$ 7,673,082	\$ -	\$ 4,808,651
State Appropriations	(3,000,000)	-	-
Tobacco Tax Collections	-	7,883,694	7,883,694
Interest Income	-	26,405	26,405
Federal Draws	304,022	6,004,701	6,004,701
TOTAL REVENUES	\$ 4,977,104	\$ 13,914,801	\$ 18,723,452

			FY 17		FY 18		
ENDITURES		Exp	penditures	Ex	penditures		Total \$ YTD
Program Costs:	_						
	Employer Sponsored Insur			\$	9,879,671	\$	9,879,671
	College Students/ESI Den	tal			74,001		29,645
Individual Plan							
	SoonerCare Choice			\$	20,658	\$	8,276
	Inpatient Hospital				562,152		225,198
	Outpatient Hospital				663,553		265,819
	BH - Inpatient Services-DF	RG			63,811		25,563
	BH -Psychiatrist				-		-
	Physicians				798,986		320,074
	Dentists				7,842		3,141
	Mid Level Practitioner				3,380		1,354
	Other Practitioners				84,393		33,808
	Home Health				496		199
	Lab and Radiology				130,407		52,241
	Medical Supplies				69,928		28,013
	Clinic Services				190,047		76,133
	Ambulatory Surgery Cente	r			30,042		12,035
	Prescription Drugs				2,098,142		840,516
	Transportation				18,090		7,247
	Premiums Collected						(109,131)
Total Individual Plan				\$	4,741,926	\$	1,790,484
	College Students-Service	e Cos	ts	\$	50,445	\$	20,208
Total OHCA Program	Costs			\$	14,746,045	\$	11,720,009
Administrative Costs							
Administrative Costs	Salaries	Ф	40.250	¢	252 606	¢	202.055
		\$	40,359	Φ	352,696	Φ	393,055
	Operating Costs Health Dept-Postponing		24,305		2,345		26,650
	Contract - HP		103,788		81,714		185,502
Total Administrative (	Costs	\$	168,452	\$	436,755	\$	605,207
Total Expenditures						\$	12,325,216
NET CASH BALANCE		\$	4,808,651			\$	6,398,235
NET CASH BALANCE		Ψ	4,000,051			Ψ	0,390,233

Fund 250: Belle Maxine Hilliard Breast and Cervical Cancer Treatment Revolving Fund SFY 2018, For the Two Month Period Ending August 31, 2017

REVENUES	FY 18 Revenue	State Share	
Tobacco Tax Collections	\$ 157,318	\$ 157,318	
TOTAL REVENUES	\$ 157,318	\$ 157,318	

		FY 18		FY 18		Total
EXPENDITURES	T	otal \$ YTD	S	state \$ YTD	Sta	te \$ Cost
Program Costs						
SoonerCare Choice	\$	2,174	\$	609		
Inpatient Hospital		124,146	\$	34,811		
Outpatient Hospital		574,802	\$	161,175		
Inpatient Services-DRG		-	\$	-		
Psychiatrist		-	\$	-		
TFC-OHCA		7,616	\$	2,136		
Nursing Facility		-	\$	-		
Physicians		855,855	\$	239,982		
Dentists		2,098	\$	588		
Mid-level Practitioner		197	\$	55		
Other Practitioners		19,511	\$	5,471		
Home Health		105	\$	30		
Lab & Radiology		34,873	\$	9,778		
Medical Supplies		5,358	\$	1,502		
Clinic Services		30,102	\$	8,441		
Ambulatory Surgery Center		1,051	\$	295		
Prescription Drugs		479,521	\$	134,458		
Transportation		18,550	\$	5,201		
Miscellaneous Medical		866		243		
<b>Total OHCA Program Costs</b>	\$	2,156,823	\$	604,773		
OSA DMHSAS Rehab	\$	13,077	\$	3,667		
Total Medicaid Program Costs	\$	2,169,900	\$	608,440		
TOTAL STATE SHARE OF COSTS					\$	608,440

Note: Expenditure amounts are for informational purposes only. Actual payments are made from Fund 340. Revenues deposited into the fund are transferred to Fund 340 to support the costs, not to exceed the calculated state share amount.


### OHCA Board Meeting October 12, 2017 (August 2017 Data)

SOONERCARE ENR	OLLMENT/EXPEND	DITURES						
Delivery System  SoonerCare Choice Patient-Centered  Medical Home		Enrollment August 2017	Children August 2017	Adults August 2017	Enrollment Change	Total Expenditures August 2017	PMPM August 2017	Forecasted August 2017 Trend PMPM
		541,867	446,057	95,810	3,539	\$184,297,027		
Lower Cost	(Children/Parents; Other)	497,692	431,987	65,705	3,456	\$132,298,787	\$266	\$205
Higher Cost	(Aged, Blind or Disabled; TEFRA; BCC)	44,175	14,070	30,105	83	\$51,998,240	\$1,177	\$993
SoonerCare Traditio	onal	236,459	88,892	147,567	-337	\$208,292,059		
Lower Cost	(Children/Parents; Other)	122,077	83,973	38,104	-683	\$51,402,131	\$421	\$460
Higher Cost	(Aged, Blind or Disabled; TEFRA; BCC & HCBS Waiver)	114,382	4,919	109,463	346	\$156,889,928	\$1,372	\$1,250
SoonerPlan		33,760	2,798	30,962	617	\$362,073	\$11	\$10
Insure Oklahoma		19,812	489	19,323	113	\$8,013,444		
Employer-Sponsored Insurance		14,603	313	14,290	63	\$5,385,370	\$369	\$342
Individual Plan		5,209	176	5,033	50	\$2,628,074	\$505	\$440
TOTAL		831,893	538,236	293,657	3,927	\$400,964,603		


Enrollment totals include all members enrolled during the report month. Members may not have expenditure data. Children are members aged 0 - 20 or for Insure Oklahoma enrolled as Students or Dependents.


Total In-State Providers: 31,757 (+505) (In-State Providers counted multiple times due to multiple locations, programs, types, and specials								nd specialties)
Physician	Pharmacy	Dentist	Hospital	Mental Health	Optometrist	Extended Care	Total PCPs	PCMH
9,540	980	1,342	186	3,360	578	389	6,804	2,681


### PER MEMBER PER MONTH COST BY GROUP



Low Cost includes members qualified under Children/Parents (TANF) and Other; High Cost members qualify under Aged, Blind or Disabled, Oklahoma Cares, TEFRA or a Home and Community-Based Services waiver.









# Medical Authorization & Review Transformation

October 12, 2017
OHCA Board Meeting

Garth Splinter, M.D.

# What are Prior Authorizations?

- Requesting authorization for specific services to treat a patient
- Done prior to treatment
- Approved based on medical necessity
- Allows claim to be processed
- This discussion does not include dental, pharmacy, or behavioral health



# Why Do We Have Prior Authorizations?

To review high-cost services prior to service being done

- To review services prone to over utilization
- To decrease the number of services that have to be questioned after they're already done

# **Outsourcing History**

- Prior to November 2010 In-house, manual processing
- November 2010 Imaging PAs outsourced
- July 2014 Therapies (speech, physical, occupational) PAs outsourced



# **Outsourcing History**

- August 2015 Radiation and cardiology outsourced
   added to imaging contract
- August 2015 Joint surgeries, spine surgeries and pain management outsourced – added to therapies contract

# **Contract Amendments: Bringing Processing Back** In-house

- November 1, 2016 Contract amendments
  - Cancelled outsourcing of cardiology, large joint surgeries, spine surgeries, pain management, and radiation therapy code set
- July 1, 2017 Contract expiration
  - Cancelled imaging and therapies (speech, physical, occupational) code set
- Plan was to release RFP (September 2016) for all nine code sets





# Original Plan: Continue Outsourcing

- An RFP was developed requesting individual bids on each code set.
- RFP not released due to agency constraints (budget) and IT resources).
- Only remaining feasible option was to bring all PA processing in-house.





# Expanding In-house PA Processing

- Organizational Changes
  - Created a new durable medical equipment (DME) unit
  - Shifted two management positions eliminating one level of management
  - Created new Medical Support Services Unit to support new PA volume balancing and rules development functions
- Staffing increased (four new staff, two currently) frozen; nine contracted FTEs; two temporary staff)






# Expanding In-house PA Processing

- Implemented automated processing (AP)
  - Low touch, less rigorous review
  - Designed to have future rules added for more efficient processing
- Purchased InterQual® software
  - Supports determination of medical necessity using evidence-based logic
  - Currently only on staff desktops
- Developed appropriate metrics




# **Controlling the Chaos**





# Claims Effect from November 2016 Vendor Amendment Cancellation





# **Anticipated Budget Effects**

Contract
Claims Volume
InterQual
Additional AP Rules
Staff/ Contracts

Net Savings

Year 1 Year 5 \$6,000,000 \$6,000,000 (\$920,000) \$1,600,000 (\$1,575,000) (\$1,300,000) (\$625,000) (\$100,000) (\$700,000) (\$700,000) \$2,180,000 \$5,500,000

- InterQual Connect® implementation
  - Automated, evidence-based guidelines
  - Question & Answer format for providers
  - Integrated with SoonerCare Provider Portal
  - Increase OHCA's ability to process PAs using rules
  - Improve process to determine whether manual review is needed
  - OHCA is able to customize InterQual® guidelines



- InterQual® pilot Dec. 4, 2017 March 1, 2018
  - Hip and knee replacements
  - Full implementation spring/summer 2018 including processing rules
- Continue to look at what services should be prior authorized
- Build business rules
- Staff using InterQual® internally now





- Staff job functions will change over time as more automation goes into effect
  - Random auditing of PA automated decisions
  - Use expertise to evaluate PA requests which fall outside normal parameters
  - Recommend business rule and guideline changes



Manual Processing	Some Automation	Increasingly Rules Based Processing	
← October 2016	Nov 2016 – Nov 2017	December 2017 →	



# Medical Authorizations and Review Team List

Garth Splinter, M.D.

Mike Herndon, D.O.

Yasmine Barve, R.N.

Jean Krieske, R.N.

Jeannie Vigneron, R.N.

Kristall Bright, R.N.

Stan Ruffner

Natasha Kester

Karen Beam, R.N.

Jami Adams

Kimberely Helton

Fred Oraene, MBA

Sarah Walker

Jennifer Gaskill

**Braden Mitchell** 

Melanie Lawrence, PMP

Deputy Chief Executive Officer

Chief Medical Officer

Dir., Medical Professional Services

Dir., Medical Admin. Support Services

Medical Auth. & Review Supervisor

Medical Auth. & Review Supervisor

**DMEPOS Program Director** 

Medical Administrative Lead

Medical Admin. Support Services Nurse

System Analyst III

Professional Svcs. Contract Manager

Dir., Office of Data Gov. and Analytics

**Clinical Outcomes Analyst** 

Research Analyst

**Project Manager** 

Sr. Project Manager








# SoonerCare Tobacco Cessation Strategies

October 12, 2017

# **Adult Smoking Rates**

- Oklahoma adult smoking rate according to Behavioral Risk Factor Surveillance System (BRFSS)
  - 19.6 percent in 2016
    - Down from 22.1 percent in 2015
- Oklahoma Medicaid adult smoking rate based on CAHPS
  - 34.4 percent in 2016
    - Down from 36.7 percent in 2015





### **Statewide Efforts**

- The Oklahoma State Department of Health Oklahoma Health Improvement Plan (OHIP2020)
  - -Tobacco use is named as one of the key areas of focus that will have the greatest impact on the health of Oklahomans now and for future generations.
- Tobacco Settlement Endowment Trust (TSET)
  - -TSET was established in 2000 following legislation to create a state question, which voters approved, to develop a trust to protect 1998 Master Settlement Agreement funds.



# Partnership -Connect4Health

- Under the Connect4Health umbrella, all SoonerCare pregnant women are automatically enrolled in Text4Baby.
- Pregnant women who opt in to the smoking cessation program through Text4Baby are enrolled in Quit4Baby.
- Individuals enrolled in Quit4baby receive educational messages, links to their state quit line and other resources.



## Partnership - TSET


- SoonerQuit for Women Media Campaign
- Oklahoma Tobacco Helpline
- SoonerQuit Grants
  - -SoonerQuit Provider Engagement
  - -SoonerQuit Health Promotion

Grants from TSET allow OHCA to draw down federal matching funds for cessation efforts




### SoonerQuit for Women

- Oklahoma Tobacco Helpline Branding
  - Media campaign including:
    - TV
    - Radio
    - Billboards
    - Transit (bus wraps, bus benches)
    - Social media
    - Website advertisements



### SoonerQuit for Women, cont.





# Oklahoma Tobacco Helpline

OHCA pays for SoonerCare members to receive the following benefits from the Helpline:

- Calls
- **Emails/Web Coach**
- Text2Quit
- **Materials**





# SoonerQuit Provider Engagement

- Utilizes practice facilitation to assist providers with implementing evidence-based best practices
- Trains, educates and provides resources to physicians and their staff on SoonerCare cessation benefits and the Oklahoma Tobacco Helpline
- Began in 2010





# SoonerQuit Provider Engagement, cont.

 Provided facilitation to 82 providers since August 2014

 Reviewed 450 fax referrals to the Oklahoma Tobacco Helpline from OHCA referral partners in SFY 17

# SoonerQuit Provider **Engagement SFY 16 Evaluation**

	Pre-Facilitation	Post-Facilitation
OTH Referrals	66	532



# SoonerQuit Provider Engagement SFY 16 Evaluation

	Baseline survey	6 month follow- up	12 month follow- up
Always billed SoonerCare	16%	41%	71%
Sometimes billed SoonerCare	48%	52%	29%
Never billed SoonerCare	36%	7%	0%



# SoonerQuit Health Promotion

 Works with community partners, members and providers to promote awareness and increase utilization of cessation services

Internal policy changes to enhance and increase access to benefits

Began in 2015



# **OHCA Policy Changes**

- Nicotine replacement therapy (NRT) and pharmacotherapy
  - No copay
  - No prior authorization
  - No duration limits
  - Does not count towards monthly prescription limit
  - Covers combination therapy





## OHCA Policy Changes, cont.

- Member cessation counseling benefit
  - Eight (8) sessions per 12 months
  - No copay
- Documentation for cessation counseling sessions
  - No separate progress note
  - No start/stop time



### **Additional Efforts**

- Online health risk assessment
- Developed a database and internal process for Member Services and Population Care Management (PCM) departments to make a referral to the helpline on behalf of the member
- PCM trained in motivational interviewing to encourage behavior change
  - Department works with a large number of pregnant women and households with children





# **OHCA's Progress**

#### **OHCA Tobacco Cessation Services**

Members Receiving Services (unique)					
Year	Members	Percent Change	Dental	Physician	RX
SFY2016	19,147		2,886	8,654	8,948
SFY2017	21,530	12%	2,569	10,723	9,970

		*Services			
Year	Services	Percent Change	Dental	Physician	RX
SFY2016	37,890		3,302	14,996	20,467
SFY2017	43,535	15%	3,102	18,583	23,070

<sup>\*</sup>Members with multiple services in the same calendar month were rolled up as 1 service.




## OHCA's Progress, cont.

- Registered 4,899 SoonerCare members for Oklahoma Tobacco Helpline services in SFY 17
- Registered 264 pregnant SoonerCare members to the Oklahoma Tobacco Helpline in SFY 17

# OHCA's Progress, cont.

### Tobacco rates among SoonerCare members



### **Questions?**







### Ist Extraordinary Session of the 56th Legislature

#### Report for Oct. 12, 2017

Oklahoma's special session convened Monday, Sept. 25, and adjourned to the call of the chair on Wednesday, Sept. 27. At the time of this report, the House was expected to reconvene on Monday, Oct. 9, to continue floor work.

#### **Interim Studies**

OHCA is tracking 48 interim studies related to health care, appropriations and state employee relations. On Wednesday, Oct. 11, Becky Pasternik-Ikard will present on House Interim Study 2017-115, which concerns boards that control authorities.

#### Cigarette tax

OHCA continues to monitor HB1099X, a cigarette tax bill that passed the House JCAB 19-9 and the Senate JCAB 10-2 on Tuesday, Sept. 26. It can now go to the House floor.

#### **HOPE Act**

HB1093X, one of three HOPE Act bills, received a do-pass recommendation from the House Rules committee on Thursday, Sept. 28. HB1093X would require OHCA to conduct a myriad of data checks before determining eligibility and carries a fiscal impact to the agency.



# Statewide Transition Plan Overview

October 12, 2017
Presented by Beverly Couch

### Final Rule - Background/Intent

- The final home and community-based services (HCBS) regulations were published in the Federal Register on January 16, 2014, and became effective March 17, 2014.
- The intent of the rule is to ensure that individuals receiving Medicaid-funded HCBS have the opportunity to receive services in a manner that protects individual choice and promotes community integration.



### **Transition Period**

- All states are required to submit Statewide Transition Plan (STP).
- The Centers for Medicare & Medicaid Services (CMS) extended the transition period, allowing states more time to comply.
  - States are now required to be in compliance with the new HCBS requirements by March 17, 2022



### **STP: What Is It?**

■ The Statewide Transition Plan (STP) is the vehicle through which states determine their compliance with the regulation requirements for HCBS settings found at 42 CFR 441.301(c)(4)(5) and 441.710(a)(1)(2) and describes to CMS how they will comply with the new requirements.

### **HCBS Setting Requirements**

Are integrated in and support full access to the greater community

Provide opportunities to seek employment and work in competitive integrated settings, engage in community life and control personal resources

Ensure the individual receives services in the community to the same degree of access as individuals not receiving Medicaid HCBS

Are selected by the individual from among setting options that include non-disability specific settings

Ensure an individual's rights of privacy, respect and freedom from coercion and restraint

Optimize individual, autonomy and independence in making life choices

Facilitate individual choice regarding services and supports and who provides them

### Oklahoma HCBS Settings

### **Department of Developmental Services (DDS)** and Aging Settings

Specialized foster care

Daily living supports

Group home services

Adult day health

Supported employment

Prevocational services

Agency companion

Assisted living

Parent's/Relative's or own home





### **Oklahoma STP Includes**

- Workgroups
  - OHCA
  - DDS
  - Aging services
  - Stakeholder
- Systemic review
- Provider assessments



### Oklahoma STP Includes

- Monitoring plan
  - Remediation
  - Public input (posted plan, public meetings and comments)
  - Relocation





Drug	Used for	Cost	<u>Notes</u>
Afstyla	Hemophilia	\$50,000/month	Step therapy
Rebinyn	Hemophilia	Not yet available	Step therapy
Endari	Sickle Cell Disease	\$3,000/month	
Namenda XR	Alzheimer's	\$4,500/year	Generic < \$150/year
Fabrazyme	Fabry's Disease	\$300,000/year	1 member
Kisqali	Breast cancer	\$11,000/month	
Kisqali/Femara	Breast cancer	\$11,000/month	
Nerlynx	Breast cancer	\$11,000/month	



### Recommendation 1: Prior Authorize Afstyla® [Antihemophilic Factor (Recombinant), Single Chain] and Rebinyn® [Coagulation Factor IX (Recombinant), GlycoPEGylated]

The Drug Utilization Review Board recommends the prior authorization of Afstyla® [antihemophilic factor (recombinant), single chain] and Rebinyn® [coagulation factor IX (recombinant), glycoPEGylated] with the following criteria:

#### Eloctate<sup>™</sup>, Adynovate<sup>®</sup>, Afstyla<sup>®</sup>, Alprolix<sup>®</sup>, Idelvion<sup>®</sup>, and Rebinyn<sup>®</sup> Approval Criteria:

- 1. An FDA approved indication; and
- 2. Requested medication must be prescribed by a hematologist specializing in hemophilia, or a mid-level practitioner with a supervising physician that is a hematologist specializing in hemophilia; and
- 3. A patient-specific, clinically significant reason why the member cannot use the following:
  - a. Hemophilia A: Advate® or current factor VIII replacement product; or
  - b. Hemophilia B: Benefix® or current factor IX replacement product; and
- 4. A half-life study must be performed to determine the appropriate dose and dosing interval; and
- 5. Initial approvals will be for the duration of the half-life study. If the half-life study shows significant benefit in prolonged half-life, subsequent approvals will be for the duration of one year.

#### **Recommendation 2: Prior Authorize Endari™ (L-Glutamine)**

The Drug Utilization Review Board recommends the prior authorization of Endari™ (L-glutamine) with the following criteria:

#### Endari™ (L-Glutamine) Approval Criteria:

- 1. An FDA approved diagnosis of sickle cell disease; and
- 2. Member must be at least 5 years of age or older; and
- 3. A trial of hydroxyurea or documentation why hydroxyurea is not appropriate for the member; and
- 4. Endari™ must be prescribed by, or in consultation with, a hematologist or a specialist with expertise in treatment of sickle cell disease (or in consultation with an advanced care practitioner with a supervising physician who is a hematologist or specialist with expertise in treating sickle cell disease); and
- 5. The member's recent weight must be provided on the prior authorization request in order to authorize the appropriate amount of drug required according to package labeling.
- 6. Initial approvals will be for a duration of six months. Reauthorization may be granted if the prescriber documents the member is responding well to treatment.

Recommendation 3: Prior Authorize Namenda XR® (Memantine Extended-Release Capsules)

The Drug Utilization Review Board recommends the prior authorization of Namenda XR® (memantine ER capsules) with the following criteria:

#### Namenda XR® [Memantine Extended-Release (ER) Capsules] Approval Criteria:

- 1. An FDA approved diagnosis for the treatment of moderate-to-severe Alzheimer's type dementia; and
- 2. A patient-specific, clinically significant reason why the member cannot use memantine immediaterelease tablets.

#### Recommendation 4: Prior Authorize Fabrazyme® (Agalsidase Beta)

The Drug Utilization Review Board recommends the prior authorization of Fabrazyme® (agalsidase beta) with the following criteria:

#### Fabrazyme® (Agalsidase Beta) Approval Criteria:

- 1. An FDA approved diagnosis of Fabry disease. Diagnosis must be confirmed by one of the following:
  - a. Genetic testing confirming positive galactosidase alpha (GLA) gene mutation; or
  - b. Decreased plasma levels of alpha-galactosidase A (less than 5% of normal); and
- 2. Fabrazyme® (agalsidase beta) will initially be approved for six months. After that time, compliance will be required for continued authorization; and
- 3. The member's recent weight must be provided on the prior authorization request in order to authorize the appropriate amount of drug required according to package labeling.

### Recommendation 5: Prior Authorize Kisqali® (Ribociclib), Kisqali® Femara® Co-Pack (Ribociclib/Letrozole), and Nerlynx™ (Neratinib)

The Drug Utilization Review Board recommends the prior authorization of Kisqali® (ribociclib), Kisqali® Femara® Co-Pack (ribociclib/letrozole), and Nerlynx™ (neratinib) with the following criteria:

#### Kisqali® (Ribociclib) Approval Criteria:

- 1. A patient-specific, clinically significant reason why the member cannot use the co-packaged formulation with letrozole; and
- 2. A diagnosis of advanced or metastatic breast cancer, initial therapy; and
- 3. Member must be Hormone Receptor (HR)-positive; and
- 4. Member must be Human Epidermal Receptor Type 2 (HER2)-negative; and
- 5. Ribociclib must be given in combination with an aromatase inhibitor; and
- 6. Ribociclib must be used in postmenopausal women only.
- 7. Authorizations will be for the duration of three months. Reauthorization may be granted if the patient does not show evidence of progressive disease while on ribociclib therapy.

#### Kisqali<sup>®</sup> Femara<sup>®</sup> Co-Pack (Ribociclib/Letrozole) Approval Criteria:

- 1. A diagnosis of advanced or metastatic breast cancer, initial therapy; and
- 2. Member must be Hormone Receptor (HR)-positive; and
- 3. Member must be Human Epidermal Receptor Type 2 (HER2)-negative; and
- 4. Ribociclib must be used in postmenopausal women only.
- 5. Authorizations will be for the duration of three months. Reauthorization may be granted if the patient does not show evidence of progressive disease while on ribociclib/letrozole therapy.

#### **Nerlynx™** (Neratinib) Approval Criteria:

- 1. For adjuvant treatment in early stage breast cancer; and
- 2. Member must have Human Epidermal Receptor Type 2 (HER2)-overexpressed breast cancer; and
- 3. Neratinib must be used to follow adjuvant trastuzumab-based therapy.
- 4. Authorizations will be for the duration of three months. Reauthorization may be granted if the patient does not show evidence of progressive disease while on neratinib therapy.